Home » Stocks » WINT

Windtree Therapeutics, Inc. (WINT)

Stock Price: $6.67 USD 0.00 (0.00%)
Updated November 27, 1:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 112.87M
Revenue (ttm) n/a
Net Income (ttm) -32.49M
Shares Out 16.92M
EPS (ttm) -2.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $6.67
Previous Close $6.67
Change ($) 0.00
Change (%) 0.00%
Day's Open 6.19
Day's Range 6.19 - 6.69
Day's Volume 6,548
52-Week Range 5.24 - 9.90

More Stats

Market Cap 112.87M
Enterprise Value 94.39M
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 16.92M
Float n/a
EPS (basic) -2.30
EPS (diluted) -2.27
FCF / Share -1.59
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 119,333
Short Ratio 7.92
Short % of Float n/a
Beta 0.11
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.42
Revenue n/a
Operating Income -27.91M
Net Income -32.49M
Free Cash Flow -26.32M
Net Cash 18.48M
Net Cash / Share 1.09
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -15.41%
ROE -50.45%
ROIC -3,495.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$12.25*
Low
12.3
Current: $6.67
High
12.3
Target: 12.25
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.201.791.492.040.992.840.390.200.58-
Revenue Growth-88.93%20.4%-27.28%106.89%-65.19%630.67%98.97%-66.49%--
Gross Profit0.201.791.492.040.060.16-0.130.200.58-
Operating Income-24.89-16.20-22.55-38.04-39.83-43.26-44.51-37.82-24.51-25.53
Net Income-27.48-20.53-18.45-39.49-55.17-44.06-45.22-37.32-20.97-19.18
Shares Outstanding10.931.500.340.140.120.100.070.050.030.01
Earnings Per Share-2.51-23.20-72.42-284.52-478.81-470.41-688.79-797.99-781.19-1,385.99
Operating Cash Flow-24.66-15.78-21.05-33.59-33.50-41.17-40.45-32.88-22.70-24.27
Capital Expenditures-0.190.01-0.02-0.25-0.19-0.78-0.61-0.64-0.11-0.10
Free Cash Flow-24.85-15.77-21.07-33.84-33.69-41.95-41.06-33.52-22.80-24.37
Cash & Equivalents22.7325.322.045.8138.9544.9486.6127.2910.5910.61
Total Debt6.317.97-25.0025.0020.3618.500.220.290.44
Net Cash / Debt16.4217.342.04-19.1913.9524.5768.1127.0810.3010.17
Assets1191193.359.7044.3847.5089.3229.9413.3214.54
Liabilities44.0451.2827.2738.5336.1128.3030.8212.2912.068.51
Book Value74.9468.11-23.92-28.838.2719.2058.5017.651.266.03
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Windtree Therapeutics, Inc.
Country United States
Employees 31
CEO Craig E. Fraser

Stock Information

Ticker Symbol WINT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: WINT
IPO Date August 8, 1995

Description

Windtree Therapeutics, a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.